American Heart Journal
Volume 147, Issue 6 , Pages 939-941 , June 2004

High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events

  • Gregg C Fonarow, MD, FACC

      Affiliations

    • UCLA Preventative Cardiology Program, Los Angeles, Calif, USA
    • Corresponding Author InformationReprint requests: Gregg C. Fonarow, MD, FACC, UCLA Preventative Cardiology Program, UCLA Division of Cardiology, 47-123 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095-1679, USA.
    • ,
  • Karol E Watson, MD, PhD

      Affiliations

    • UCLA Preventative Cardiology Program, Los Angeles, Calif, USA

References 

  1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease (a meta-analysis of randomized controlled trials). JAMA. 1999;282:2340–2346
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  3. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals (a randomised placebo-controlled trial). Lancet. 2002;360:7–22
  4. Wood D, De Backer G, Faergeman O, et al.  Prevention of coronary heart disease in clinical practice (recommendations of the second joint task force of European and other societies on coronary prevention). Eur Heart J. 1998;19:1434–1503
  5. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106:2526–2529
  6. Castelli WP, Garrison RJ, Wilson PW, et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels (the Framingham Study). JAMA. 1986;256:2835–2838
  7. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-age adults during the era of hypertensive therapy (the Framingham offspring study). Am J Med. 1991;90:11–16
  8. Sharrett AR, Patsch W, Sorlie PD, et al.  Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease (the Atherosclerosis Risk in Communities (ARIC) study). Arterioscler Thromb. 1994;14:1098–1104
  9. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol. 2000;86:11–14L
  10. Shah PK, Kaul S, Nilsson J, et al.  Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins (an idea whose time for testing is coming, part I). Circulation. 2001;104:2376–2383
  11. Navab M, Berliner JA, Subbanagounder G, et al.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481–488
  12. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high-density lipoprotein and suppresses atherosclerosis in the apolipoprotein E- deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607–9611
  13. De Geest B, Zhao Z, Collen D, et al.  Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation. 1997;96:4349–4356
  14. Navab M, Anantharamaiah GM, Hama S, et al.  Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290–292
  15. Dean BB, Borenstein JE, Henning JM, et al. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 2004;147:966–76
  16. Pasternak RC. The ALLHAT lipid lowering trial—less is less. JAMA. 2002;288:3042–3044
  17. Shah PK, Kaul S, Nilsson J, et al.  Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins (an idea whose time for testing is coming, part II). Circulation. 2001;104:2498–2502
  18. Nissen SE, Tsunoda T, Tuzcu EM, et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes (a randomized controlled trial). JAMA. 2003;290:2292–2300

PII: S0002-8703(04)00052-3

doi: 10.1016/j.ahj.2004.01.014

American Heart Journal
Volume 147, Issue 6 , Pages 939-941 , June 2004

Article Tools